Have a personal or library account? Click to login
The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review Cover

The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review

Global Heart
Volume 17 (2022): Issue 1
By: Muhammad Jami Husain,  Garrison Spencer,  Rachel Nugent,  Deliana Kostova and  Patricia Richter  
Open Access
|Mar 2022

References

  1. 1Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results; 2018, Seattle, United States: Institute for Health Metrics and Evaluation (IHME).
    Back to article
  2. 2Stanaway JD, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1923–1994. DOI: 10.1016/S0140-6736(18)32225-6
    Back to article
  3. 3Khatib R, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PloS One. 2014; 9(1): e84238. DOI: 10.1371/journal.pone.0084238
    Back to article
  4. 4Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. The American Journal of Cardiology. 2012; 110(6): 823–825. DOI: 10.1016/j.amjcard.2012.04.062
    Back to article
  5. 5Santos RD, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The Lancet. Diabetes & Endocrinology. 2016; 4(10): 850–861. DOI: 10.1016/S2213-8587(16)30041-9
    Back to article
  6. 6Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532–2561. DOI: 10.1016/S0140-6736(16)31357-5
    Back to article
  7. 7Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934): 1383–9. DOI: 10.1016/S0140-6736(94)90566-5
    Back to article
  8. 8Wilson PWF, et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139: e1144–e1161. DOI: 10.1161/CIR.0000000000000626
    Back to article
  9. 9Taylor F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 2013(1): CD004816.
    Back to article
  10. 10Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B): 2889–934.
    Back to article
  11. 11Cholesterol Treatment Trialists C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–81. DOI: 10.1016/S0140-6736(10)61350-5
    Back to article
  12. 12Murray CJ, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003; 361(9359): 717–25. DOI: 10.1016/S0140-6736(03)12655-4
    Back to article
  13. 13Mitchell AP, Simpson RJ, Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012; 5: 373. DOI: 10.1186/1756-0500-5-373
    Back to article
  14. 14Pandya A, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015; 314(2): 142–50. DOI: 10.1001/jama.2015.6822
    Back to article
  15. 15De Smedt D, et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: The EUROASPIRE III health economics project. Eur Heart J. 2012; 33(22): 2865–72. DOI: 10.1093/eurheartj/ehs210
    Back to article
  16. 16Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B): 2889–934.
    Back to article
  17. 17National Clinical Guideline Centre (UK). Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014; London: National Institute for Health and Clinical Excellence.
    Back to article
  18. 18Anderson TJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016; 32(11): 1263–1282. DOI: 10.1016/j.cjca.2016.07.510
    Back to article
  19. 19Bibbins-Domingo K, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA - Journal of the American Medical Association. 2016; 316(19): 1997–2007. DOI: 10.1001/jama.2016.15450
    Back to article
  20. 20Piepoli MF, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381. DOI: 10.1093/eurheartj/ehw106
    Back to article
  21. 21World Health Organization. WHO Model Lists of Essential Medicines. Available from: https://www.who.int/medicines/publications/essentialmedicines/en/.
    Back to article
  22. 22Jeemon P, et al. Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease. In Cardiovascular, Respiratory, and Related Disorders, Prabhakaran D, et al., (eds.). 2017; Washington, DC. DOI: 10.1596/978-1-4648-0518-9_ch22
    Back to article
  23. 23Basu S, Bendavid E, Sood N. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis. Circ. Cardiovasc. Qual. Outcomes. 2015; 8(6): 541–551. DOI: 10.1161/CIRCOUTCOMES.115.001994
    Back to article
  24. 24Briseño GG, Mino-León D. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. Current Medical Research and Opinion. 2010; 26(5): 1075–81. DOI: 10.1185/03007991003694498
    Back to article
  25. 25Rubinstein A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010; 10: 627. DOI: 10.1186/1471-2458-10-627
    Back to article
  26. 26Sansanayudh N, et al. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. 2010; 44: 415–23. DOI: 10.1345/aph.1M522
    Back to article
  27. 27Khonputsa P, et al. Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand. Value Health Reg. Issues. 2012; 1(1): 15–22. DOI: 10.1016/j.vhri.2012.03.019
    Back to article
  28. 28Mould-Quevedo JF, et al. Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia. Value Health Reg. Issues. 2014; 5: 48–57. DOI: 10.1016/j.vhri.2014.07.007
    Back to article
  29. 29Ribeiro RA, et al. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system. Arquivos brasileiros de cardiologia. 2015; 104(1): 32–44. DOI: 10.5935/abc.20140173
    Back to article
  30. 30Borissov B, et al. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: Measuring health benefit by effectively treated patient-years (ETPY). Value Health. 2017; 20(5): A270. DOI: 10.1080/20016689.2017.1412753
    Back to article
  31. 31Konfino J, et al. Comparing strategies for lipid lowering in Argentina: An analysis from the CVD policy model-Argentina. Journal of General Internal Medicine. 2017; 32: 524–533. DOI: 10.1007/s11606-016-3907-8
    Back to article
  32. 32Li T, et al. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Advances in Therapy. 2018; 35(12): 2214–2223. DOI: 10.1007/s12325-018-0823-9
    Back to article
  33. 33Kongpakwattana K, et al. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. Pharmacoeconomics. 2019; 37(10): 1277–1286. DOI: 10.1007/s40273-019-00820-6
    Back to article
  34. 34Yang H, et al. Cost-effectiveness analysis of Ezetimibe as the add-on treatment to moderate-dose rosuvastatin versus high-dose rosuvastatin in the secondary prevention of cardiovascular diseases in China: A Markov model analysis. Drug Des. Dev. Ther. 2020; 14: 157–165. DOI: 10.2147/DDDT.S213968
    Back to article
  35. 35Salomon JA, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ. 2012; 344: e355. DOI: 10.1136/bmj.e355
    Back to article
  36. 36Amirsadri M, Hassani A. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men. Daru. 2015; 23: 56. DOI: 10.1186/s40199-015-0129-2
    Back to article
  37. 37Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2011; 26(3): 210–22. DOI: 10.1093/heapol/czq045
    Back to article
  38. 38Wood A, et al. Prevention of cardiovascular disease in a rural region of India and strategies to address the unmet need. Heart. 2011; 97(17): 1373–1378. DOI: 10.1136/hrt.2011.225987
    Back to article
  39. 39Tumanan-Mendoza BA, Mendoza VL. Economic evaluation of lipid-lowering therapy in the secondary prevention setting in the Philippines. Value Health Reg. Issues. 2013; 2(1): 13–20. DOI: 10.1016/j.vhri.2013.01.003
    Back to article
  40. 40Megiddo I, et al. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: A modeling study. Global Heart. 2014; 9(4): 391–398.e3. DOI: 10.1016/j.gheart.2014.07.002
    Back to article
  41. 41Ngalesoni FN, et al. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study. BMC Health Services Research. 2016; 16: 185. DOI: 10.1186/s12913-016-1409-3
    Back to article
  42. 42Tolla MT, et al. Prevention and treatment of cardiovascular disease in Ethiopia: A cost-effectiveness analysis. Cost Eff. Resour. Allocat. 2016; 14(1): 1–14. DOI: 10.1186/s12962-016-0059-y
    Back to article
  43. 43Ortegon M, et al. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: Mathematical modelling study. BMJ. 2012; 344: e607. DOI: 10.1136/bmj.e607
    Back to article
  44. 44Bautista LE, et al. A ‘polypill’ aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Affairs (Project Hope). 2013; 32(1): 155–64. DOI: 10.1377/hlthaff.2011.0948
    Back to article
  45. 45Lin JK, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Ghana, and South Africa. Circulation. 2016; 134(suppl_1): A14538–A14538.
    Back to article
  46. 46WHO. Choosing Interventions that are Cost Effective (WHO-CHOICE) – Cardiovascular Disease. Geneva: World Health Organization.
    Back to article
  47. 47Bertram MY, et al. Cost-effectiveness thresholds: Pros and cons. Bulletin of the World Health Organization. 2016; 94(12): 925–930. DOI: 10.2471/BLT.15.164418
    Back to article
  48. 48World Economic Forum, WHO. From burden to “best buys”: Reducing the economic impact of non-communicable diseases in low- and middle-income countries. Geneva: World Economic Forum; 2011. Available at http://www.who.int/nmh/publications/best_buys_summary.pdf.
    Back to article
  49. 49Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial. Lancet. 2019; 394(10199): 672–683. DOI: 10.1016/S0140-6736(19)31791-X
    Back to article
  50. 50Lancet. Polypills: An essential medicine for cardiovascular disease. Lancet. 2017; 389(10073): 984. DOI: 10.1016/S0140-6736(17)30695-5
    Back to article
  51. 51The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet. 2009; 373(9672): 1341–1351. DOI: 10.1016/S0140-6736(09)60611-5
    Back to article
  52. 52World Health Organization. Essential medicines selection. Aspirin + statin + antihypertensive – addition – EML. 20th Expert Committee on the Selection and Use of Essential Medicines. https://www.who.int/selection_medicines/committees/expert/20/applications/aspirin_statin_antihyper_Ad/en/.
    Back to article
DOI: https://doi.org/10.5334/gh.1097 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Nov 5, 2021
Accepted on: Jan 26, 2022
Published on: Mar 4, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Hyperlipidemia,
Cost-effectiveness,
Low and Middle Income Countries

© 2022 Muhammad Jami Husain, Garrison Spencer, Rachel Nugent, Deliana Kostova, Patricia Richter, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 17 (2022): Issue 1Next article